Delcath Systems, Inc.

The momentum for this stock is not very good. Delcath Systems, Inc. is not a good value stock. Delcath Systems, Inc. is not very popular among insiders. Delcath Systems, Inc. is a mediocre stock to choose.

News

Delcath Systems management to meet with BTIG

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors

Simply Wall St Delcath Systems, Inc. ( NASDAQ:DCTH ) shares have continued their recent momentum with a 26% gain in the last month...\n more…

Delcath Systems (NASDAQ:DCTH) Downgraded to "Sell" at StockNews.com

Ticker Report StockNews.com downgraded shares of Delcath Systems (NASDAQ:DCTH - Free Report) from a hold rating to a sell rating in a research report sent to investors on Monday morning. A number of other equities...\n more…

Delcath Systems (NASDAQ:DCTH) Rating Lowered to Sell at StockNews.com

Zolmax StockNews.com downgraded shares of Delcath Systems (NASDAQ:DCTH - Free Report) from a hold rating to a sell rating in a report released on Monday morning.\nOther analysts have also issued research...\n more…

Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will participate in a...\n more…

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

Business Wire Delcath Systems, Inc. (Nasdaq: DCTH) (the Company or Delcath), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the...\n more…